RHHBY Roche Holding Ltd ADR (Sponsored)

34.7
+0.14  (+0%)
Previous Close 34.56
Open 34.74
Price To Book 8.24
Market Cap 237,642,606,054
Shares 6,848,490,088
Volume 1,653,245
Short Ratio
Av. Daily Volume 1,172,663

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due 3Q 2019 with final data due 1Q 2020.
Mytesi (crofelemer) HALT-D
Cancer related diarrhea (CRD)
Phase 3 data did not meet primary endpoint - June 20, 2019.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
First patient enrolled in Phase 3 trial announced January 28, 2019.
IONIS-HTT Rx
Huntington's Disease
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 2
Alzheimer’s disease
Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due 2H 2019.
RG7916 - SUNFISH
Spinal Muscular Atrophy (SMA)
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 3 data due in 2020.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
FDA approval announced May 6, 2019.
Kadcyla (KATHERINE)
HER2-positive breast cancer - residual invasive disease
FDA approval announced August 15, 2019.
Entrectinib
Solid tumors and ROS1-positive non-small cell lung cancer (NSCLC)
Phase 3 PFS endpoint met - PFS=6.3 vs. 5.6 months for chemo. HR 0.71.
Tecentriq+cb+pac/nab-pac - IMpower131
Squamous non-small cell lung cancer (NSCLC)
FDA Approval announced December 6, 2018.
Tecentriq + Avastin - IMpower150
Non-squamous non-small cell lung cancer (NSCLC)
PFS endpoint met. HR 0.74 - February 6, 2018.
TECENTRIQ (atezolizumab) - IMmotion151
Kidney cancer - renal cell carcinoma (mRCC)
Approval announced June 7, 2018.
MabThera/ Rituxan (rituximab)
Pemphigus vulgaris
Phase 3 data released July 19, 2018. PFS endpoint met, OS endpoint not yet met - final OS data due 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower132
Squamous non-small cell lung cancer (NSCLC)
FDA approval announced March 18, 2019.
Tecentriq+cb+etoposide - IMpower133
Squamous non-small cell lung cancer (NSCLC)
PDUFA date for sBLA September 2, 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130
Squamous non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2019.
IMspire150 - cobimetinib, atezolizumab and vemurafenib - TRILOGY
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
FDA Approval announced October 4, 2018.
Hemlibra
Hemophilia
Phase 3 updated data due at 27 September-1 October 2019
Alecensa - ALEX
Anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-small cell lung cancer (NSCLC)
Phase 1b additional four cohorts added - noted July 15, 2019.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
FDA approval announced June 13, 2018.
Avastin (bevacizumab) + chemo
Ovarian cancer
Phase 3 enrollment has commenced - noted June 14, 2018.
Gantenerumab
Early Alzheimer's disease
FDA Approval announced October 24, 2018.
Baloxavir marboxil
Influenza
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML
FDA approval announced May 15, 2019.
Venetoclax and obinutuzumab
Chronic Lymphocytic Leukemia
FDA Approval announced March 8, 2019.
TECENTRIQ (atezolizumab) plus Abraxane
Triple-negative breast cancer
Phase 3 interim analysis passed.
Tecentriq + chemo - IMpassion 031
Neoadjuvant triple negative breast cancer
Phase 3 data due 2H 2019.
Tecentriq + Avastin - IMbrave 150
Hepatocellular carcinoma
Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%.
Venclexta plus Gazyva
Chronic lymphocytic leukemia (CLL)
Phase 3 data due 2H 2019.
Venclexta MIRROS
Acute myeloid leukemia (AML)
Phase 3 primary endpoint met.
Venclexta BELLINI
Multiple myeloma
FDA approval announced June 10, 2019.
Polatuzumab vedotin and bendamustine plus Rituxan (rituximab)
Diffuse large B-cell lymphoma (DLBCL)
PDUFA date for sNDA November 4, 2019.
Baloxavir marboxil
Influenza
Phase 3 OS update at ASCO June 4, 2019 - median OS=21.0 vs 18.7 months; HR=0.86.
Tecentriq plus nab-paclitaxel - IMpassion 130
Triple-negative breast cancer
Phase 3 data due 2019.
Idasanutlin (RG7388) - MIRROS
Acute myeloid leukemia (AML)
Phase 3 trials met primary endpoints - June 3, 2019.
Xolair (omalizumab)
Chronic rhinosinusitis with nasal polyps (CRSwNP)
PDUFA date under priority review, sBLA accepted June 12, 2019. No PDUFA date released. Estimate October 11, 2019 assuming sBLA was filed two months prior to acceptance.
MabThera/ Rituxan (rituximab)
Granulomatosis with polyangiitis (GPA) / microscopic polyangiitis (MPA)
Phase 3 trial met primary and secondary endpoints - June 13, 2019.
Mabthera/Rituxan (rituximab) - PEMPHIX
Pemphigus vulgaris
Phase 3 data due 2020.
Ranibizumab
Neovascular Age-Related Macular Degeneration
Phase 3 data due 2H 2019.
Tecentriq - IMvigor010
Urothelial cancer
Phase 3 PFS co-primary endpoint met - August 5, 2019.
Tecentriq (atezolizumab) plus chemotherapy
Urothelial carcinoma
FDA approval announced August 15, 2019.
Entrectinib
Solid tumors - NTRK gene fusion

Latest News

  1. UPDATE 2-Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi
  2. Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
  3. Roche prices personalized cancer treatment at about $204,560 annually
  4. AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL
  5. Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
  6. The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission
  7. FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
  8. FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors
  9. UPDATE 2-Roche's personalized cancer treatment wins FDA approval
  10. Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat
  11. Accenture (ACN) to Acquire INSITUM to Boost Interactive Suite
  12. Here's Why Amgen Stock is Outperforming Its Industry Of Late
  13. J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients
  14. Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up
  15. Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients
  16. Senseonics Holdings, Inc. (SENS) Q2 2019 Earnings Call Transcript
  17. Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid
  18. Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance
  19. Gundlach: The yield curve is ‘full-on recessionary’
  20. Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold